Main page      Statistics      Risk factors      Genetics      Diagnosis      Others      Directory

TRAIL-2 expression is related to breast cancer survival

 Return to main news page


     High expression of TRAIL-R2, has been shown to be associated with a decrease the survival rates of breast cancer patients according to a study published by Yale Cancer Center researchers in Clinical Cancer Research. TRAIL is a member of cytokines family of tumor necrosis factor (TNF) . TRAIL family of cytokines induces apoptosis in a wide variety of cells. TRAIL-2, a member of this TRAIL group has remarkable ability to induce apoptosis.

    Analyzing 20-year follow-up data from breast cancer patients, using an automated quantitative analysis system (AQUATM) to review tissue micro-array specimens, the researchers identified increased intensity of TRAIL receptor expression. AQUATM scores were correlated with clinical and pathologic variables. In addition, TRAIL-R1 and TRAIL-R2 expression were both studied on 95 unmatched normal breast specimens.

    Yale Researchers concluded that while TRAIL-R1 expression was not associated with survival, high TRAIL-R2 expression strongly correlated with decreased survival.

    "A number of TRAIL receptor targeting therapies are currently in clinical development. As with other targeted therapies, it is important to determine which patients are more likely to respond to these therapies," said Harriet Kluger, MD, author on the study and Assistant Professor of Medicine in the Section of Medical Oncology at Yale School of Medicine. "AQUATM allows us to stratify patients based on expression levels of drug targets in an automated, unbiased fashion. This will help us reach our ultimate goal of practicing personalized medicine, by treating patients based on characteristics of individual tumors,"

    The AQUATM system measures and localizes specific variations in protein expression within tissue automatically, with a high level of precision. The multi-tissue proteomic analysis system combines fluorescence-based imaging with automated microscopy and high-throughput tissue microarray technologies. HistoRx has exclusively licensed the AQUATM technology that was developed by David Rimm, M.D., Ph.D. and Robert Camp, M.D., of the Yale University School of Medicine and Yale Cancer Center.


    Ref: Clinical Cancer Research 2005;11(14) July 15, 2005